Table of Contents

Research Articles

• Research Articles | AuthorChoice

  Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

  Eric R. Lutz, Annie A. Wu, Elaine Bigelow, Rajni Sharma, Guanglan Mo, Kevin Soares, Sara Solt, Alvin Dorman, Anthony Wamwea, Allison Yager, Daniel Laheru, Christopher L. Wolfgang, Jiang Wang, Ralph H. Hruban, Robert A. Anders, Elizabeth M. Jaffee and Lei Zheng

  Cancer Immunol Res July 1 2014 2 (7) 616-631; DOI:10.1158/2326-6066.CIR-14-0027

  
  

  Lutz and colleagues show that an allogeneic vaccine given with or without low-dose cyclophosphamide converted pancreatic cancer into an immunogenic cancer with infiltrating effector lymphocytes and formation of tertiary lymphoid aggregates that are regulatory structures of adaptive immunity.

• Research Articles

  Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

  F. Stephen Hodi, Donald Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada, Wanyong Zeng, Anita Giobbie-Hurder, Michael B. Atkins, Nageatte Ibrahim, Philip Friedlander, Keith T. Flaherty, George F. Murphy, Scott Rodig, Elsa F. Velazquez, Martin C. Mihm Jr, Sara Russell, Pamela J. DiPiro, Jeffrey T. Yap, Nikhil Ramaiya, Annick D. Van den Abbeele, Maria Gargano and David McDermott

  Cancer Immunol Res July 1 2014 2 (7) 632-642; DOI:10.1158/2326-6066.CIR-14-0053

  
  

  Hodi and colleagues report the safety and efficacy of targeting angiogenesis and CTLA-4 in a phase I trial of 46 patients with metastatic melanoma, which revealed the influence of VEGF-A blockade on inflammation, lymphocyte trafficking, and immune regulation, and their synergistic therapeutic effects.

• Research Articles

  Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

  Zachary A. Cooper, Vikram R. Juneja, Peter T. Sage, Dennie T. Frederick, Adriano Piris, Devarati Mitra, Jennifer A. Lo, F. Stephen Hodi, Gordon J. Freeman, Marcus W. Bosenberg, Martin McMahon, Keith T. Flaherty, David E. Fisher, Arlene H. Sharpe and Jennifer A. Wargo

  Cancer Immunol Res July 1 2014 2 (7) 643-654; DOI:10.1158/2326-6066.CIR-13-0215

  
  

  Cooper, Juneja, Sage, and colleagues show that combining BRAF and PD-1/PD-L1 blockade slowed tumor growth and prolonged survival in a melanoma mouse model, with increased number and activity of tumor-infiltrating lymphocytes similar to that in a human melanoma patient treated with this regimen.

• Research Articles | AuthorChoice

  The Tumor Microenvironment Shapes Lineage, Transcriptional, and Functional Diversity of Infiltrating Myeloid Cells

  Kutlu G. Elpek, Viviana Cremasco, Hua Shen, Christopher J. Harvey, Kai W. Wucherpfennig, Daniel R. Goldstein, Paul A. Monach and Shannon J. Turley

  Cancer Immunol Res July 1 2014 2 (7) 655-667; DOI:10.1158/2326-6066.CIR-13-0209

  
  

  Elpek and colleagues analyzed the developmental and transcriptomic signatures of infiltrating myeloid cells in three mouse tumor models and report that tumor-associated macrophages and neutrophils exhibited different frequencies, gene expression profiles, and functions dependent on cancer types but not locations.

• Research Articles

  Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

  Benjamin Weide, Thomas K. Eigentler, Annette Pflugfelder, Henning Zelba, Alexander Martens, Graham Pawelec, Leonardo Giovannoni, Pier Adelchi Ruffini, Giuliano Elia, Dario Neri, Ralf Gutzmer, Jürgen C. Becker and Claus Garbe

  Cancer Immunol Res July 1 2014 2 (7) 668-678; DOI:10.1158/2326-6066.CIR-13-0206

  
  

  Weide and colleagues show that intralesional therapy using the immunocytokine L19–IL2 elicited a high rate of clinical and systemic immune responses in patients with stage III melanoma and report their observation of favorable distant metastasis-free and overall survival in these patients after treatment.

• Research Articles

  ERK-Dependent Downregulation of the Atypical Chemokine Receptor D6 Drives Tumor Aggressiveness in Kaposi Sarcoma

  Benedetta Savino, Nicoletta Caronni, Achille Anselmo, Fabio Pasqualini, Elena Monica Borroni, Gianluca Basso, Giuseppe Celesti, Luigi Laghi, Athanasia Tourlaki, Vinicio Boneschi, Lucia Brambilla, Manuela Nebuloni, Gianluca Vago, Alberto Mantovani, Massimo Locati and Raffaella Bonecchi

  Cancer Immunol Res July 1 2014 2 (7) 679-689; DOI:10.1158/2326-6066.CIR-13-0202

  
  

  Savino, Caronni, and colleagues report that D6 expression was inversely correlated with increased tumor-associated M2-macrophages and aggressiveness in ERK pathway–activated Kaposi sarcoma (KS), and suggest targeting of CCR2 and the ERK pathway as a therapeutic option for patients with KS.

• Research Articles

  Programmed Cell Death Ligand 1 Expression in Osteosarcoma

  Jacson K. Shen, Gregory M. Cote, Edwin Choy, Pei Yang, David Harmon, Joseph Schwab, G. Petur Nielsen, Ivan Chebib, Soldano Ferrone, Xinhui Wang, Yangyang Wang, Henry Mankin, Francis J. Hornicek and Zhenfeng Duan

  Cancer Immunol Res July 1 2014 2 (7) 690-698; DOI:10.1158/2326-6066.CIR-13-0224

  
  

  Shen, Cote, and colleagues developed a quantitative RNA-based PD-L1 assay and report PD-L1 expression in 84% of human osteosarcomas, of which 24% were at high levels and correlated with TILs, indicating that this subset of patients may benefit from anti-PD-L1 immunotherapy.